Canaccord Genuity Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); DIFICID Launch Starts Strong
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $20.00.
Canaccord analyst, George Farmer, said, "Directionally positive sales results and script trends support our view of strong DIFICID potential for treatment of C. diff. infection (CDI)...Longer term, we see the differentiated clinical profile of DIFICID, including low CDI recurrence risk, enabling steady inroads into a market currently dominated by generic competition. Modeling for modest penetration, foremost in patients failing standard-of-care vancomycin, we see peak sales of $285M in 2015...Adding potential upside, a European regulatory decision on DIFICID, partnered in EU with Astellas, is expected in Q1/12."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.79 yesterday.
Canaccord analyst, George Farmer, said, "Directionally positive sales results and script trends support our view of strong DIFICID potential for treatment of C. diff. infection (CDI)...Longer term, we see the differentiated clinical profile of DIFICID, including low CDI recurrence risk, enabling steady inroads into a market currently dominated by generic competition. Modeling for modest penetration, foremost in patients failing standard-of-care vancomycin, we see peak sales of $285M in 2015...Adding potential upside, a European regulatory decision on DIFICID, partnered in EU with Astellas, is expected in Q1/12."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
- Cummins (CMI) PT Lowered to $675 at Jefferies
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
